Pramlintide
FDA-approved amylin analog (Symlin) injected at mealtimes as an insulin adjunct for glucose and weight control
Half-life
~48 min
Typical Dose
15-60mcg (type 1) or 60-120mcg (type 2) SC before major meals
Format
Injectable
Purity
Pharmaceutical grade (prescription drug)
Overview
Pramlintide is the pharmaceutical amylin analog, marketed as Symlin and approved by the FDA in 2005 as a mealtime adjunct to insulin in type 1 and type 2 diabetes [2,3]. Taken before meals, it improves long-term glycemic control while trimming body weight, the opposite of the weight gain that usually accompanies insulin intensification [2,3]. In obese subjects without diabetes it produced placebo-corrected weight loss of about 3.7% over 16 weeks [1], rising to roughly 6-7kg over 12 months at higher doses [5]. It carries a boxed warning for severe insulin-induced hypoglycemia and must be injected separately from insulin. Think of it as the short-acting, clinically validated cousin of Cagrilintide, the long-acting once-weekly amylin analog we cover.
Mechanism
Pramlintide is a synthetic analog of amylin, the 37-amino-acid hormone co-secreted with insulin by pancreatic beta cells. Three proline substitutions replace the aggregation-prone residues of native human amylin so the molecule stays soluble and injectable. Acting largely at amylin receptors in the area postrema, it slows gastric emptying, suppresses postprandial glucagon, and increases satiety [4]. Controlled meal tests show it lowers energy intake by roughly 16-23% without shortening meal duration [4], which underpins the weight and glycemic effects seen when it is added to insulin [2]. These are the same receptor pathways that Cagrilintide exploits, but pramlintide acts for minutes rather than a week.
Researched benefits
- Blunts post-meal glucose spikes as an insulin adjunct
- Suppresses inappropriate postprandial glucagon secretion
- Slows gastric emptying for steadier glucose absorption
- Increases satiety and reduces energy intake
- Modest weight loss instead of the weight gain typical of insulin intensification
- The only FDA-approved amylin analog to date
Frequently asked
What is amylin, and what does pramlintide do?
Amylin is a hormone co-secreted with insulin by pancreatic beta cells at every meal. Native human amylin clumps and is impractical as a drug, so pramlintide swaps in three proline residues to keep it soluble. It slows gastric emptying, suppresses post-meal glucagon, and signals satiety to the brain, complementing what insulin does for glucose.
Is Symlin used together with insulin?
Yes. Symlin is only approved as an adjunct to mealtime insulin, never as a standalone therapy. It is given as a separate subcutaneous injection because it cannot be mixed with insulin in the same syringe. Labeling advises cutting mealtime insulin by about 50% when starting pramlintide to reduce early hypoglycemia risk.
What is the boxed warning about hypoglycemia?
Symlin carries an FDA boxed warning for severe insulin-induced hypoglycemia, seen mainly in type 1 diabetes and usually within three hours of injection. Pramlintide does not cause low blood sugar on its own, but combined with mealtime insulin the risk rises, which is why insulin doses are reduced and glucose is monitored closely at initiation.
Pramlintide vs Cagrilintide: what is the difference?
Both are amylin analogs, but they are built for different jobs. Pramlintide is short-acting (roughly 48-minute half-life), dosed before each meal, and FDA-approved as an insulin adjunct for diabetes. Cagrilintide is engineered for a ~7-day half-life and once-weekly dosing, and is being developed for obesity, notably paired with semaglutide as CagriSema. Pramlintide is the drug that first validated amylin agonism in humans.
What is the typical dose and half-life?
In type 1 diabetes pramlintide starts at 15mcg and titrates to 30-60mcg before major meals; in type 2 diabetes it starts at 60mcg and can go to 120mcg. The plasma half-life is about 48 minutes, which is why it is dosed per meal rather than daily or weekly. Obesity research used higher ranges of 120-360mcg.
How is Symlin stored and administered?
No mixing or reconstitution is needed; the SymlinPen is prefilled and ready to use. Keep unopened pens refrigerated at 2-8°C, and discard an in-use pen after 30 days. Inject subcutaneously into the abdomen or thigh (not the arm, due to variable absorption) immediately before eating, at a site separate from any insulin injection.
Scientific Literature
References
- [1]
Aronne L, Fujioka K, Aroda V, et al. (2007). Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.
Journal of Clinical Endocrinology & Metabolism · PubMed: 17504894
- [2]
Hollander PA, Levy P, Fineman MS, et al. (2003). Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
Diabetes Care · PubMed: 12610038
- [3]
Ratner RE, Dickey R, Fineman M, et al. (2004). Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
Diabetic Medicine · PubMed: 15498087
- [4]
Chapman I, Parker B, Doran S, et al. (2005). Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.
Diabetologia · PubMed: 15843914
- [5]
Smith SR, Aronne LJ, Burns CM, et al. (2008). Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.
Diabetes Care · PubMed: 18753666
Citations are provided for educational purposes. Always verify primary sources before drawing research conclusions.
Ready to start your research
Get Pramlintide from Ascension Peptides
COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.
Buy Pramlintide now